Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis
Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging 2016, 18: 1057-1064. PMID: 27965280, DOI: 10.1093/ehjci/jew298.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBortezomibBostonCardiomyopathiesCohort StudiesEchocardiography, Doppler, ColorFemaleFollow-Up StudiesHeart Function TestsHospitals, UniversityHumansImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedPrognosisRetrospective StudiesROC CurveSensitivity and SpecificitySurvival AnalysisTreatment OutcomeVentricular Dysfunction, LeftConceptsB-type natriuretic peptideFree light chainsLight-chain cardiac amyloidosisCardiac amyloidosisCardiac biomarkersCR groupGlobal LSHigh-dose melphalanLongitudinal systolic strainSerum free light chainsCardiac functional impairmentCardiac functional improvementStandard echocardiographic measuresCardiac function improvementShort-term improvementBNP reductionComplete responseDiastolic functionEchocardiographic measuresHematologic responseNatriuretic peptideSystolic strainFunctional improvementFunction improvementFunctional impairment